Merus NV
NASDAQ:MRUS

Watchlist Manager
Merus NV Logo
Merus NV
NASDAQ:MRUS
Watchlist
Price: 45.49 USD 2.56% Market Closed
Market Cap: 3.1B USD
Have any thoughts about
Merus NV?
Write Note

Merus NV
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Merus NV
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Merus NV
NASDAQ:MRUS
Operating Income
-$231m
CAGR 3-Years
-37%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Operating Income
-$14.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-2%
ProQR Therapeutics NV
NASDAQ:PRQR
Operating Income
-€26.7m
CAGR 3-Years
20%
CAGR 5-Years
13%
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Operating Income
-$194.7m
CAGR 3-Years
N/A
CAGR 5-Years
-12%
CAGR 10-Years
-17%
argenx SE
XBRU:ARGX
Operating Income
-$432.1m
CAGR 3-Years
-13%
CAGR 5-Years
-25%
CAGR 10-Years
-57%
LAVA Therapeutics NV
NASDAQ:LVTX
Operating Income
-$43.3m
CAGR 3-Years
-43%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Merus NV
Glance View

Market Cap
3.1B USD
Industry
Biotechnology

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. The company is headquartered in Utrecht, Utrecht and currently employs 121 full-time employees. The company went IPO on 2016-05-19. The firm develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products include, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as well as MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

MRUS Intrinsic Value
25.57 USD
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Merus NV's Operating Income?
Operating Income
-231m USD

Based on the financial report for Sep 30, 2024, Merus NV's Operating Income amounts to -231m USD.

What is Merus NV's Operating Income growth rate?
Operating Income CAGR 5Y
-43%

Over the last year, the Operating Income growth was -42%. The average annual Operating Income growth rates for Merus NV have been -37% over the past three years , -43% over the past five years .

Back to Top